Bausch Health Q3 2026 slides: 14th straight growth quarter, guidance raised
Bausch Health (BHC) reported Q3 2026 revenue of $2.941B, up 10%, and adjusted EBITDA of $1.305B, up 32%. All segments grew, with Salix leading at 16%. The company raised full-year guidance and reduced net debt by $521M. Shares rose 9.67% to $6.92 in regular trading and 13.15% to $7.83 after-hours.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift drove a near 10% intraday rally, suggesting continued momentum.
Market read
Strong earnings and guidance raise for BHC may influence healthcare sector sentiment and trigger buying interest.
What to watch
Potential impact of 2027 Medicare pricing changes on Xifaxan revenue.
Background
Bausch Health presented its Q3 2026 earnings, marking 14 consecutive quarters of growth and raising full‑year guidance.
Ticker impact
Bausch Health reported Q3 2026 results with 10% revenue growth, $1.305B adjusted EBITDA and raised full-year guidance, causing a 9.7% share surge.
likely further upside as investors price in stronger guidance and robust cash flow.
The company delivered double‑digit growth, exceeded EBITDA expectations and lifted guidance, which historically supports continued price appreciation.
Market effects
Highlights strength in diversified healthcare and may lift peer pharma stocks.
Positive for North American healthcare sector indices.
Reinforces confidence in global pharma earnings trends.
Counterpoint
Some analysts may question sustainability of growth given upcoming Medicare pricing headwinds.
Key entities
- companyBausch Health Companies Inc.
US‑listed diversified healthcare firm reporting earnings.
